{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:21:23Z","timestamp":1792801283124,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Chinese Academy of Medical Sciences Cancer Hospital - Shenzhen Hospital Cooperation Fund","award":["No. CFA202202018"],"award-info":[{"award-number":["No. CFA202202018"]}],"id":[{"id":"https:\/\/ror.org\/02drdmm93","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the clinical characteristics and treatment outcomes of women with recurrent uterine leiomyosarcoma (uLMS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study to evaluate the clinical characteristics and survival of women with recurrent uLMS and identify prognostic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 71 patients with first recurrence of uLMS were included in our study. 19 patients (26.8%) received systemic therapy and 52 patients (73.2%) received secondary cytoreductive surgery (SCS). In SCS subgroup (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200952), a complete resection with no residual disease was performed in 47 patients (90.4%). 38.5% (20\/52) patients received non-reproductive organ surgeries. 10 (19.2%) patients had received thoracic surgery because of lung-only recurrence. Bowel, bladder surgery was performed in 8 (15.4%), 3 (5.8%) patients, respectively. 1 (1.9%) patient had received liver surgery. The median follow-up duration was 38.7 months (range: 2.7-317.6 months). 41 (57.7%) patients died during follow-up. 5-year OS for the entire cohort was 52.9%. Patients experienced first recurrence after initial diagnoses within 12 months (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200924) had a worse 5-year OS than those after 12 months (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200947) (17.0% vs. 69.1%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). 5-year OS for the SCS and non-SCS subgroup was 62.0% and 28.0%, respectively (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Multivariate analysis showed time to fist recurrence within 12 months (HR\u2009=\u20094.60, 95% CI: 1.49\u201314.4,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.008) was an independent predictor of decreased 5-year OS in SCS subgroup.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SCS is an important treatment choice for recurrent uLMS and seems to have benefited patients. Time to fist recurrence within 12 months is an independent predictor of decreased 5-year OS in SCS subgroup.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-024-03415-3","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T04:02:14Z","timestamp":1729828934000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical characteristics and treatment outcomes of women with recurrent uterine leiomyosarcoma"],"prefix":"10.1186","volume":"19","author":[{"given":"Hua","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwen","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"issue":"Suppl 2","key":"3415_CR1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/ijgo.12613","volume":"143","author":"N Mbatani","year":"2018","unstructured":"Mbatani N, Olawaiye AB, Prat J. Uterine sarcomas. Int J Gynaecol Obstet. 2018;143(Suppl 2):51\u20138.","journal-title":"Int J Gynaecol Obstet"},{"key":"3415_CR2","volume-title":"World Health Organization classification of tumours of the female reproductive organs","author":"RJ Kurman","year":"2014","unstructured":"Kurman RJ, Carcanigiu ML, Herrington S, Young RH. World Health Organization classification of tumours of the female reproductive organs. Lyon: IARC; 2014."},{"key":"3415_CR3","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/cncr.23245","volume":"112","author":"DS Kapp","year":"2008","unstructured":"Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer. 2008;112:820\u201330.","journal-title":"Cancer"},{"key":"3415_CR4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ejogrb.2023.06.016","volume":"287","author":"A Giannini","year":"2023","unstructured":"Giannini A, Golia D\u2019Aug\u00e8 T, Bogani G, Lagan\u00e0 AS, Chiantera V, Vizza E, et al. Uterine sarcomas: a critical review of the literature. Eur J Obstet Gynecol Reprod Biol. 2023;287:166\u201370.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"3415_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ygyno.2020.01.022","volume":"157","author":"K Takehara","year":"2020","unstructured":"Takehara K, Yamashita N, Watanabe R, Teramoto N, Tsuda H, Motohashi T, et al. Clinical status and prognostic factors in Japanese patients with uterine leiomyosarcoma. Gynecol Oncol. 2020;157:115\u201320.","journal-title":"Gynecol Oncol"},{"key":"3415_CR6","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.ygyno.2018.09.010","volume":"151","author":"ME Roberts","year":"2018","unstructured":"Roberts ME, Aynardi JT, Chu CS. Uterine leiomyosarcoma: a review of the literature and update on management options. Gynecol Oncol. 2018;151:562\u201372.","journal-title":"Gynecol Oncol"},{"key":"3415_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ygyno.2017.02.012","volume":"145","author":"B-LL Seagle","year":"2017","unstructured":"Seagle B-LL, Sobecki-Rausch J, Strohl AE, Shilpi A, Grace A, Shahabi S. Prognosis and treatment of uterine leiomyosarcoma: a National Cancer Database study. Gynecol Oncol. 2017;145:61\u201370.","journal-title":"Gynecol Oncol"},{"key":"3415_CR8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ygyno.2007.02.031","volume":"106","author":"RL Giuntoli","year":"2007","unstructured":"Giuntoli RL, Garrett-Mayer E, Bristow RE, Gostout BS. Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. Gynecol Oncol. 2007;106:82\u20138.","journal-title":"Gynecol Oncol"},{"key":"3415_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/PGP.0000000000000284","volume":"36","author":"C Bartosch","year":"2017","unstructured":"Bartosch C, Afonso M, Pires-Lu\u00eds AS, Galaghar A, Guimar\u00e3es M, Antunes L, et al. Distant metastases in Uterine Leiomyosarcomas: the wide Variety of Body sites and Time Intervals to metastatic relapse. Int J Gynecol Pathol. 2017;36:31\u201341.","journal-title":"Int J Gynecol Pathol"},{"key":"3415_CR10","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1097\/IGC.0000000000000221","volume":"24","author":"JA Rauh-Hain","year":"2014","unstructured":"Rauh-Hain JA, Hinchcliff EM, Oduyebo T, Worley MJ, Andrade CA, Schorge JO, et al. Clinical outcomes of women with recurrent or persistent uterine leiomyosarcoma. Int J Gynecol Cancer. 2014;24:1434\u201340.","journal-title":"Int J Gynecol Cancer"},{"key":"3415_CR11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1006\/gyno.2002.6840","volume":"87","author":"MM Leitao","year":"2002","unstructured":"Leitao MM, Brennan MF, Hensley M, Sonoda Y, Hummer A, Bhaskaran D, et al. Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma. Gynecol Oncol. 2002;87:287\u201394.","journal-title":"Gynecol Oncol"},{"key":"3415_CR12","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1136\/ijgc-2019-000355","volume":"29","author":"N Bizzarri","year":"2019","unstructured":"Bizzarri N, Ghirardi V, Di Fiore GLM, De Iaco P, Gadducci A, Casarin J, et al. Secondary cytoreductive surgery in recurrent uterine leiomyosarcoma: a multi-institutional study. Int J Gynecol Cancer. 2019;29:1134\u201340.","journal-title":"Int J Gynecol Cancer"},{"key":"3415_CR13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/IGC.0b013e3181c9e289","volume":"20","author":"R Bernstein-Molho","year":"2010","unstructured":"Bernstein-Molho R, Grisaro D, Soyfer V, Safra T, Merimsky O. Metastatic uterine leiomyosarcomas: a single-institution experience. Int J Gynecol Cancer. 2010;20:255\u201360.","journal-title":"Int J Gynecol Cancer"},{"key":"3415_CR14","volume-title":"WHO classification of soft tissue and bone tumours","author":"WHO Classification of Tumors Editorial Board","year":"2020","unstructured":"WHO Classification of Tumors Editorial Board. WHO classification of soft tissue and bone tumours. 5th ed. Lyon, France: International Agency for Research on Cancer; 2020.","edition":"5"},{"key":"3415_CR15","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/PGP.0000000000000141","volume":"33","author":"E Oliva","year":"2014","unstructured":"Oliva E. Cellular mesenchymal tumors of the uterus: a review emphasizing recent observations. Int J Gynecol Pathol. 2014;33:374\u201384.","journal-title":"Int J Gynecol Pathol"},{"key":"3415_CR16","first-page":"2229","volume":"35","author":"N Bacalbasa","year":"2015","unstructured":"Bacalbasa N, Balescu I, Dima S, Brasoveanu V, Popescu I. Prognostic factors and survival in patients treated surgically for primary and recurrent uterine leiomyosarcoma: a single center experience. Anticancer Res. 2015;35:2229\u201334.","journal-title":"Anticancer Res"},{"key":"3415_CR17","first-page":"499","volume":"8","author":"K Nakamura","year":"2018","unstructured":"Nakamura K, Kajiyama H, Utsumi F, Suzuki S, Niimi K, Sekiya R, et al. Secondary cytoreductive surgery potentially improves the oncological outcomes of patients with recurrent uterine sarcomas. Mol Clin Oncol. 2018;8:499\u2013503.","journal-title":"Mol Clin Oncol"},{"key":"3415_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ygyno.2019.05.015","volume":"154","author":"P Cybulska","year":"2019","unstructured":"Cybulska P, Sioulas V, Orfanelli T, Zivanovic O, Mueller JJ, Broach VA, et al. Secondary surgical resection for patients with recurrent uterine leiomyosarcoma. Gynecol Oncol. 2019;154:333\u20137.","journal-title":"Gynecol Oncol"},{"key":"3415_CR19","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1186\/s12885-017-3484-1","volume":"17","author":"C Villala\u00edn-Gonz\u00e1lez","year":"2017","unstructured":"Villala\u00edn-Gonz\u00e1lez C, Tejerizo-Garc\u00eda \u00c1, Lopez-Garcia P, L\u00f3pez-Gonz\u00e1lez G, Oliver-Perez MR, Jim\u00e9nez-L\u00f3pez JS. Vaginal metastasis as the initial presentation of leiomyosarcoma: a case report. BMC Cancer. 2017;17:503.","journal-title":"BMC Cancer"},{"key":"3415_CR20","doi-asserted-by":"publisher","first-page":"e2591","DOI":"10.1016\/j.ajog.2013.11.002","volume":"210","author":"WA Jimenez","year":"2014","unstructured":"Jimenez WA, Sardi A, Nieroda C, Gushchin V. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent high-grade uterine sarcoma with peritoneal dissemination. Am J Obstet Gynecol. 2014;210:e2591\u20138.","journal-title":"Am J Obstet Gynecol"},{"key":"3415_CR21","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1016\/j.ejso.2017.08.011","volume":"43","author":"A Sardi","year":"2017","unstructured":"Sardi A, Sipok A, Baratti D, Deraco M, Sugarbaker P, Salti G, et al. Multi-institutional study of peritoneal sarcomatosis from uterine sarcoma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2017;43:2170\u20137.","journal-title":"Eur J Surg Oncol"},{"key":"3415_CR22","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/IGC.0000000000001289","volume":"28","author":"TP D\u00edaz-Montes","year":"2018","unstructured":"D\u00edaz-Montes TP, El-Sharkawy F, Lynam S, Harper A, Sittig M, MacDonald R, et al. Efficacy of Hyperthermic Intraperitoneal Chemotherapy and cytoreductive surgery in the treatment of recurrent uterine sarcoma. Int J Gynecol Cancer. 2018;28:1130\u20137.","journal-title":"Int J Gynecol Cancer"},{"key":"3415_CR23","doi-asserted-by":"crossref","unstructured":"Dermawan JK, Chiang S, Singer S, Jadeja B, Hensley ML, Tap WD et al. Developing Novel genomic risk stratification models in soft tissue and Uterine Leiomyosarcoma. Clin Cancer Res. 2024;30:2260\u201371.","DOI":"10.1158\/1078-0432.CCR-24-0148"},{"key":"3415_CR24","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S1072-7515(02)01120-1","volume":"194","author":"A Stojadinovic","year":"2002","unstructured":"Stojadinovic A, Yeh A, Brennan MF. Completely resected recurrent soft tissue sarcoma: primary anatomic site governs outcomes. J Am Coll Surg. 2002;194:436\u201347.","journal-title":"J Am Coll Surg"},{"key":"3415_CR25","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1097\/IGC.0000000000000720","volume":"26","author":"M Hosh","year":"2016","unstructured":"Hosh M, Antar S, Nazzal A, Warda M, Gibreel A, Refky B. Uterine sarcoma: analysis of 13,089 cases based on Surveillance, Epidemiology, and end results database. Int J Gynecol Cancer. 2016;26:1098\u2013104.","journal-title":"Int J Gynecol Cancer"},{"key":"3415_CR26","doi-asserted-by":"publisher","first-page":"e211658","DOI":"10.1148\/radiol.211658","volume":"306","author":"N Hindman","year":"2023","unstructured":"Hindman N, Kang S, Fournier L, Lakhman Y, Nougaret S, Reinhold C, et al. MRI evaluation of Uterine masses for risk of Leiomyosarcoma: a Consensus Statement. Radiology. 2023;306:e211658.","journal-title":"Radiology"},{"key":"3415_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ygyno.2020.10.020","volume":"160","author":"S Pedra Nobre","year":"2021","unstructured":"Pedra Nobre S, Hensley ML, So M, Zhou QC, Iasonos A, Leitao MM, et al. The impact of tumor fragmentation in patients with stage I uterine leiomyosarcoma on patterns of recurrence and oncologic outcome. Gynecol Oncol. 2021;160:99\u2013105.","journal-title":"Gynecol Oncol"},{"key":"3415_CR28","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s00066-006-1491-2","volume":"182","author":"B Kortmann","year":"2006","unstructured":"Kortmann B, Reimer T, Gerber B, Klautke G, Fietkau R. Concurrent radiochemotherapy of locally recurrent or advanced sarcomas of the uterus. Strahlenther Onkol. 2006;182:318\u201324.","journal-title":"Strahlenther Onkol"},{"key":"3415_CR29","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ijrobp.2011.06.1960","volume":"83","author":"BM Barney","year":"2012","unstructured":"Barney BM, Petersen IA, Dowdy SC, Bakkum-Gamez JN, Haddock MG. Long-term outcomes with intraoperative radiotherapy as a component of treatment for locally advanced or recurrent uterine sarcoma. Int J Radiat Oncol Biol Phys. 2012;83:191\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3415_CR30","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S1470-2045(17)30622-8","volume":"18","author":"B Seddon","year":"2017","unstructured":"Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, et al. Gemcitabine and Docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017;18:1397\u2013410.","journal-title":"Lancet Oncol"},{"key":"3415_CR31","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ygyno.2008.03.010","volume":"109","author":"ML Hensley","year":"2008","unstructured":"Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008;109:329\u201334.","journal-title":"Gynecol Oncol"},{"key":"3415_CR32","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1200\/JCO.2014.58.3781","volume":"33","author":"ML Hensley","year":"2015","unstructured":"Hensley ML, Miller A, O\u2019Malley DM, Mannel RS, Behbakht K, Bakkum-Gamez JN, et al. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology\/Gynecologic Oncology Group study. J Clin Oncol. 2015;33:1180\u20135.","journal-title":"J Clin Oncol"},{"key":"3415_CR33","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S1470-2045(15)70070-7","volume":"16","author":"P Pautier","year":"2015","unstructured":"Pautier P, Floquet A, Chevreau C, Penel N, Guillemet C, Delcambre C, et al. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2015;16:457\u201364.","journal-title":"Lancet Oncol"},{"key":"3415_CR34","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","volume":"387","author":"P Sch\u00f6ffski","year":"2016","unstructured":"Sch\u00f6ffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016;387:1629\u201337.","journal-title":"Lancet"},{"key":"3415_CR35","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1200\/JCO.23.00402","volume":"41","author":"M Ingham","year":"2023","unstructured":"Ingham M, Allred JB, Chen L, Das B, Kochupurakkal B, Gano K, et al. Phase II study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250). J Clin Oncol. 2023;41:4154\u201363.","journal-title":"J Clin Oncol"},{"key":"3415_CR36","doi-asserted-by":"publisher","first-page":"5413","DOI":"10.1158\/0008-5472.CAN-21-0356","volume":"81","author":"M Kodama","year":"2021","unstructured":"Kodama M, Shimura H, Tien JC, Newberg JY, Kodama T, Wei Z, et al. Sleeping Beauty Transposon Mutagenesis identifies genes driving the initiation and metastasis of Uterine Leiomyosarcoma. Cancer Res. 2021;81:5413\u201324.","journal-title":"Cancer Res"},{"key":"3415_CR37","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1158\/1078-0432.CCR-22-0100","volume":"28","author":"K Yoshida","year":"2022","unstructured":"Yoshida K, Yokoi A, Yamamoto T, Hayashi Y, Nakayama J, Yokoi T, et al. Aberrant activation of cell-cycle-related kinases and the potential therapeutic impact of PLK1 or CHEK1 inhibition in Uterine Leiomyosarcoma. Clin Cancer Res. 2022;28:2147\u201359.","journal-title":"Clin Cancer Res"},{"key":"3415_CR38","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ygyno.2022.11.014","volume":"168","author":"J Harold","year":"2023","unstructured":"Harold J, Bellone S, Manavella DD, Mutlu L, McNamara B, Hartwich TMP, et al. Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma. Gynecol Oncol. 2023;168:157\u201365.","journal-title":"Gynecol Oncol"},{"key":"3415_CR39","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13046-023-02687-0","volume":"42","author":"G Dall","year":"2023","unstructured":"Dall G, Vandenberg CJ, Nesic K, Ratnayake G, Zhu W, Vissers JHA, et al. Targeting homologous recombination deficiency in uterine leiomyosarcoma. J Exp Clin Cancer Res. 2023;42:112.","journal-title":"J Exp Clin Cancer Res"},{"key":"3415_CR40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s40164-023-00443-w","volume":"12","author":"S Mittal","year":"2023","unstructured":"Mittal S, Kadamberi IP, Chang H, Wang F, Kumar S, Tsaih S-W, et al. Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma. Exp Hematol Oncol. 2023;12:78.","journal-title":"Exp Hematol Oncol"},{"key":"3415_CR41","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/S0140-6736(16)30587-6","volume":"388","author":"WD Tap","year":"2016","unstructured":"Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016;388:488\u201397.","journal-title":"Lancet"},{"key":"3415_CR42","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WTA van der Graaf","year":"2012","unstructured":"van der Graaf WTA, Blay J-Y, Chawla SP, Kim D-W, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379:1879\u201386.","journal-title":"Lancet"},{"key":"3415_CR43","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","volume":"21","author":"DS Hong","year":"2020","unstructured":"Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol. 2020;21:531\u201340.","journal-title":"Lancet Oncol"},{"key":"3415_CR44","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1001\/jamaoncol.2020.3689","volume":"6","author":"SM Pollack","year":"2020","unstructured":"Pollack SM, Redman MW, Baker KK, Wagner MJ, Schroeder BA, Loggers ET, et al. Assessment of Doxorubicin and Pembrolizumab in patients with Advanced Anthracycline-naive sarcoma: a phase 1\/2 Nonrandomized Clinical Trial. JAMA Oncol. 2020;6:1778\u201382.","journal-title":"JAMA Oncol"},{"key":"3415_CR45","doi-asserted-by":"crossref","unstructured":"Livingston MB, Jagosky MH, Robinson MM, Ahrens WA, Benbow JH, Farhangfar CJ et al. Phase II study of Pembrolizumab in combination with Doxorubicin in metastatic and Unresectable Soft-Tissue Sarcoma. Clin Cancer Res. 2021;27:6424\u201331.","DOI":"10.1158\/1078-0432.CCR-21-2001"},{"key":"3415_CR46","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/cncr.28476","volume":"120","author":"S George","year":"2014","unstructured":"George S, Feng Y, Manola J, Nucci MR, Butrynski JE, Morgan JA, et al. Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and\/or progesterone receptors. Cancer. 2014;120:738\u201343.","journal-title":"Cancer"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03415-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03415-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03415-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T05:53:07Z","timestamp":1729835587000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03415-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3415"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03415-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]},"assertion":[{"value":"17 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all individuals. This study was approved by the Cancer Hospital, Chinese Academy of Medical Sciences Institutional Review Board (IRB).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from all the subjects included in the study. In the case of deceased patients, they provided their consents prior to their demise.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No potential conflicts of interest were disclosed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"395"}}